One describes mlb hall of fame game had received online baseball tickets conclude 4 cycles of this therapy,and the other received three.The targeted radiation therapy penetrates and kills cancer cells by using theCompany's patented humanized monoclonal antibody called clivatuzumab, or hPAM4,to deliver beta-radiation beams produced by the radioisotope, yttrium-90,directly to the tumor. Clivatuzumab binds to 85% of pancreatic cancers, but doesnot target cells in normal pancreas or pancreatitis.In addition to getting Y-90 clivatuzumab tetraxetan, patients also received 4weekly doses of 200 mg/m(2) of gemcitabine known to sensitize cancer cells toradiation, and which was given much below its usual therapeutic dose. The majorside effect from the combination treatment is low blood cell counts which aremanageable and reversible Otherwise, the treatment has been well tolerated. Thestudy is ongoing with the next group of patients expected to receive 15.0mCi/m(2) of Y-90 weekly for 3 weeks.Y-90 clivatuzumab tetraxetan has been designated by the U.S.

Food and DrugAdministration (FDA) as a fast-track product, and has orphan drug status in boththe U.S goose gossage signed baseball . and the European Union for the therapy of pancreatic cancer.About Y-90 Clivatuzumab TetraxetanClivatuzumab is a humanized monoclonal antibody targeting a mucin antigenexpressed in most pancreatic cancers, but not pancreatitis, normal pancreas ormost other normal tissues buy baseball tickets . Preclinical studies in mice with human pancreaticcancer xenografts given the murine version of Y-90 PAM4 demonstrated favorabletumor responses, which could be further improved when given in combination withgemcitabine ernie banks signed baseball . A prior Phase I single dose-escalation study of Y-90 clivatuzumabtetraxetan in treatment-relapsed pancreatic cancer patients has also producedencouraging results, with evidence of objective responses ernie banks autographed baseball . The radiolabeledhumanized antibody is currently in a Phase Ib fractionated dose-escalation studyin combination with gemcitabine for the treatment of patients with newlydiagnosed, untreated, stage III or stage IV cancer of the pancreas.About Pancreatic CancerAccording to the American Cancer Society, pancreatic cancer is the fourthleading cause of cancer death in the United States. In 2009, an estimated 42,470Americans will be diagnosed with the disease, and about 35,240 patients will diefrom it.

For all stages combined, the 1- and 5-year survival rates are 24% and5% respectively autographed bats . Even for those people diagnosed with local disease, the 5-yearsurvival is only 20% online baseball tickets . Currently, the standard therapy for pancreatic cancer isgemcitabine, alone or in combination with other chemotherapeutics.About ImmunomedicsImmunomedics is a New Jersey-based biopharmaceutical company primarily focusedon the development of monoclonal, antibody-based products for the targetedtreatment of cancer, autoimmune and other serious diseases buy baseball tickets . We have developed anumber of advanced proprietary technologies that allow us to create humanizedantibodies that can be used either alone in unlabeled or "naked" form, orconjugated with radioactive isotopes, chemotherapeutics or toxins, in each caseto create highly targeted agents . Using these technologies, we have built apipeline of therapeutic product candidates that utilize several differentmechanisms of action.